This protocol applies to hospitalized adults with nonsevere community-acquired pneumonia (CAP) who have a prior history of respiratory isolation of Pseudomonas aeruginosa — a recognized risk factor that warrants a modified empiric approach beyond the standard inpatient CAP regimen.
The patient is admitted with nonsevere CAP managed in the hospital setting. Prior respiratory isolation of Pseudomonas aeruginosa is documented — one of the most consistently strong individual risk factors for respiratory P. aeruginosa infection. Evidence-based guidelines recommend empiric anti-pseudomonal coverage only when locally validated risk factors such as this are present; in their absence, standard CAP therapy is preferred.
The approach augments the standard nonsevere inpatient CAP backbone therapy with empiric coverage specifically targeting P. aeruginosa. Cultures should be obtained at the outset to enable deescalation or to confirm the need for continued anti-pseudomonal therapy. The treatment target is achievement of clinical stability — defined by resolution of vital sign abnormalities, ability to eat, and normal mentation. Full agent selection and the complete regimen are detailed in the protocol.
The most consistently strong individual risk factors for respiratory infection with MRSA or P. aeruginosa are prior isolation of these organisms, especially from the respiratory tract, and/or recent hospitalization and exposure to parenteral antibiotics.
We recommend clinicians only cover empirically for MRSA or P. aeruginosa in adults with CAP if locally validated risk factors for either pathogen are present.
Add coverage for P. aeruginosa and obtain cultures to allow deescalation or confirmation of need for continued therapy.
We recommend that the duration of antibiotic therapy should be guided by a validated measure of clinical stability (resolution of vital sign abnormalities [heart rate, respiratory rate, blood pressure, oxygen saturation, and temperature], ability to eat, and normal mentation), and antibiotic therapy should be continued until the patient achieves stability and for no less than a total of 5 days (strong recommendation, moderate quality of evidence).
View source ↗